Haleon PLC (GB:HLN) has released an update.
Haleon PLC has completed a strategic off-market purchase of over 60 million shares from Pfizer Inc. for approximately £230 million, fulfilling its £500 million share buyback commitment for 2024. This transaction will also support the company’s employee share plans for 2025, and concurrently, Pfizer’s stake in Haleon will decrease from 22.6% to roughly 15%. The move aligns with Haleon’s capital allocation priorities and its objective to deliver returns for shareholders.
For further insights into GB:HLN stock, check out TipRanks’ Stock Analysis page.
